Takeda Ventures joins peers Astellas Venture Management, Genzyme Ventures and a third, unnamed corporate venturing group as strategic investor in Fate.
Japan-based drugs company Takeda Pharmaceutical’s corporate venturing unit has made an equity investment of undisclosed size in Fate Therapeutics as part of a plan to help its parent move into regenerative medicines.
Takeda Ventures joins peers Astellas Venture Management, Genzyme Ventures and a third, unnamed corporate venturing group as strategic investor in Fate.
The venture capital firms backing Fate are Arch Venture Partners, OVP Venture Partners, Polaris Venture Partners and Venrock.
Graeme Martin, executive president at Takeda Ventures,…
